Lannett Enters Supply And Distribution Agreement For Levothyroxine
Lannett enters into an agreement with Cediprof for an exclusive 10-year future supply and distribution agreement of levothyroxine starting 1 August 2022.
You may also be interested in...
Lannett has launched levothyroxine sodium capsules, an authorized generic version of Tirosint, in partnership with IBSA in the US. The company faces the possibility of competition, as Teva may enter the market with certain generic strengths.
Having failed to find a buyer for its raw materials business in Cody, US, Lannett now intends to shut down the operation.
US firm Lannett, which recently lost a key distribution deal involving a highly profitable thyroid drug, raised its sales guidance for fiscal 2019 and was upbeat on its prospects after reporting third-quarter net profit that fell by 17% to $10.6m.